Increasing access to kidney transplantation for sensitized recipient through three-way kidney paired donation with desensitization: The first Indian report

Table 2 Immunologic data in patient 1 and our cost of immune monitoring and desensitization therapy

Patient 1	Before desensitization	After desensitization
With wife donor
DSA (MFI)	A24-4924, B58-9767, DR11-13112, DR17-13598, DQ7-13194, DQ2-14751	A24-1000, B58-7055, DR11-4296, DR17-1925, DQ7-11838, DQ2-2410
AHG-CDC LCM (%)	80	20
T FCM (MCS)	212	Negative
B-FCM (MCS)	504	328
With KPD donor
DSA (MFI)	B8, 6830: DR 17, 14751: DQ2, 13112	B8, 2400: DR 17, 1925:
		DQ2, 2410
AHG-CDC (%)	20	17
T-FCM (MCS)	88	Negative
B-FCM (MCS)	335	190
The cost of immune monitoring and desensitization therapy (USD)
AHG-CDC LCM		20
T and B FCM		100
DSA ( Luminexx, qualitative)		40
DSA ( Luminexx, quantitative)		425
HLA (class 1 and 2)		200
Plasmapheresis		300
Bortezomib (Baximib, Ranbaxy) 2 mg		60
IVIg (Plasmaglob, Plasmagen) 5 gm		125
Rabbit anti-human thymocyte immunoglobulin (Thymoglobulin, Genzyme-Sanofi) 25 mg		200
Valganciclovir (Cymgal, Biocon) 450 mg		3
Methyl prednisolone ( Solumedrol, Pfizer) 125 mg		4

DSA: Donor specific antibody; AHG-CDC-LCM: An anti-human, globulin-enhanced, complement-dependent cytotoxicity lymphocytotoxicity cross matches; FCM: Flow cross match; MCS: Median channel shift; MFI: Mean fluorescent intensity; KPD: Kidney paired donation.